Michael Heffernan
Founder at COLLEGIUM PHARMACEUTICAL, INC.
Net worth: 2 M $ as of 2024-03-30
Profile
Michael Thomas Heffernan founded Collegium Pharmaceutical, Inc. in 2002, where he is working as Chairman from 2018, PreCision Dermatology, Inc. in 2010, where he worked as Director from 2010 to 2014, Clinical Studies Ltd.
in 1995, where he worked as President & Chief Executive Officer from 1995 to 1997, Onset Dermatologics LLC in 2005, where he worked as President & Chief Executive Officer from 2005 to 2011, and Avenge Bio, Inc. in 2019, where he is working as President, Chief Executive Officer & Director from 2019.
Mr. Heffernan also currently works at NMD Pharma A, as Chairman from 2023, Indalo Therapeutics, Inc., as Chairman from 2019, Trevi Therapeutics, Inc., as Lead Independent Director from 2017, Synlogic, Inc., as Independent Director from 2020, K36 Therapeutics, Inc., as Director, and Biohaven Ltd., as Lead Independent Director.
Mr. Heffernan also formerly worked at Phymatrix Corp., as Chairman, President & Chief Executive Officer from 1999 to 2002, Astellas Institute for Regenerative Medicine, as Chairman from 2013 to 2016, CTx Operations, Inc., as Chairman, Veloxis Pharmaceuticals A, as Chairman from 2016 to 2020, TYRX, Inc., as Director, Cornerstone BioPharma, Inc., as Director in 2008, Akebia Therapeutics, Inc., as Independent Director from 2018 to 2022, Cornerstone Therapeutics, Inc., as Independent Director from 2011 to 2014, Biohaven Pharmaceutical Holding Co. Ltd., as Independent Director from 2020 to 2021, Keryx Biopharmaceuticals, Inc., as Independent Director from 2016 to 2018, and Eli Lilly & Co., as Principal.
Mr. Heffernan received his undergraduate degree in 1987 from the University of Connecticut.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-05-17 | 37,815 ( 0.12% ) | 1 M $ | 2024-03-30 | |
BIOHAVEN LTD.
0.02% | 2024-03-03 | 15,178 ( 0.02% ) | 830 085 $ | 2024-03-30 |
TREVI THERAPEUTICS, INC.
0.01% | 2023-06-27 | 6,351 ( 0.01% ) | 21 911 $ | 2024-03-30 |
SYNLOGIC INC
-.--% | 2023-08-17 | 0 ( -.--% ) | - $ | 2024-03-30 |
Michael Heffernan active positions
| Companies | Position | Start |
|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC. | Founder | 2001-12-31 |
| TREVI THERAPEUTICS, INC. | Director/Board Member | 2017-01-31 |
| SYNLOGIC, INC. | Director/Board Member | 2020-12-07 |
| BIOHAVEN LTD. | Director/Board Member | 2022-09-27 |
NMD Pharma A/S
 NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | Chairman | 2023-01-02 |
Avenge Bio, Inc.
 Avenge Bio, Inc. Pharmaceuticals: MajorHealth Technology Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation. | Founder | 2019-02-28 |
Indalo Therapeutics, Inc.
 Indalo Therapeutics, Inc. BiotechnologyHealth Technology Indalo Therapeutics, Inc. operates as a biopharmaceutical firm that develops integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The company was founded by David Griggs, Williamson Z. Bradford III, Peter Ruminski, and Robert W. Karr and is headquartered in Cambridge, MA. | Chairman | 2019-12-16 |
K36 Therapeutics, Inc.
 K36 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology K36 Therapeutics, Inc. develops small molecule therapeutics. The company is based in Cambridge, MA. The company was founded in 2021. The CEO is Terry Connolly. | Director/Board Member | - |
Former positions of Michael Heffernan
| Companies | Position | End |
|---|---|---|
| BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | Director/Board Member | 2022-10-02 |
| ░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Training of Michael Heffernan
| University of Connecticut | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 5 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| COLLEGIUM PHARMACEUTICAL, INC. | Health Technology |
| AKEBIA THERAPEUTICS, INC. | Health Technology |
| TREVI THERAPEUTICS, INC. | Health Technology |
| SYNLOGIC, INC. | Health Technology |
| Private companies | 17 |
|---|---|
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
TYRX, Inc.
 TYRX, Inc. Electronic Equipment/InstrumentsElectronic Technology TYRX, Inc. designs and manufactures medical-pharmaceutical combination devices. The firm commercializes implantable combination drug and device products focused on infection control including the AIGISRx Antibacterial Envelope, designed to reduce surgical site infections associated with cardiac implantable electronic devices (CIEDs). Its AIGISRx products contain the antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection by pathogens responsible for the majority of CIED infections, including superbugs such as methicillin-resistant S. aureus (MRSA). The company was founded in 1998 by Satish Pulapura and Arikha Moses and is headquartered in Monmouth Junction, NJ. | Electronic Technology |
Cornerstone BioPharma, Inc.
 Cornerstone BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Cornerstone BioPharma, Inc. develops and commercializes biopharmaceutical products for respiratory disorders. Its products include AlleRx, Balacet, Deconsal, and Spectracef. The company was founded in March 2004 by Craig A. Collard, Chenyqua Baldwin, and Steven Lutz and is headquartered in Cary, NC | Health Technology |
Veloxis Pharmaceuticals A/S
 Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark. | Health Technology |
PreCision Dermatology, Inc.
 PreCision Dermatology, Inc. Pharmaceuticals: MajorHealth Technology PreCision Dermatology, Inc. developed skincare therapies. It offered pharmaceutical products for skin barrier restoration, dermatoses, rosacea, acne, seborrheic dermatitis, and scaling associated with hyperkeratotic skin. The company was founded by Jeffrey M. Nugent in 2010 and was headquartered in Cumberland, RI. | Health Technology |
Clinical Studies Ltd.
 Clinical Studies Ltd. Miscellaneous Commercial ServicesCommercial Services Clinical Studies Ltd. provides multi-therapeutic, Phase I-IV clinical research studies. The company is based in Providence, RI. The company was founded by Michael Thomas Heffernan. Clinical Studies was acquired by Comprehensive NeuroScience, Inc. from Innovative Clinical Solutions Ltd. on February 08, 2002. | Commercial Services |
| Phymatrix Corp. | Health Services |
Astellas Institute for Regenerative Medicine
 Astellas Institute for Regenerative Medicine Pharmaceuticals: MajorHealth Technology Astellas Institute for Regenerative Medicine engages in the development and commercialization of human pluripotent stem cell technology in the field of regenerative medicine. The company also have a preclinical development pipeline in areas outside of ophthalmology, including; autoimmune diseases, inflammatory diseases, and wound healing. The company was founded on May 18, 2000 and is headquartered in Marlborough, MA. | Health Technology |
Cornerstone Therapeutics, Inc.
 Cornerstone Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cornerstone Therapeutics, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for the hospital, rare disease and adjacent specialty care settings. It acquires, develops and commercializes prescription pharmaceutical drugs. The company was founded on October 31, 2008 and is headquartered in Cary, NC. | Health Technology |
Onset Dermatologics LLC
 Onset Dermatologics LLC Pharmaceuticals: MajorHealth Technology Onset Dermatologics LLC develops and markets prescription product for skin disorders. The company was founded in 2005 and is headquartered in Cumberland, RI. | Health Technology |
Biohaven Pharmaceutical Holding Co. Ltd.
 Biohaven Pharmaceutical Holding Co. Ltd. Pharmaceuticals: MajorHealth Technology Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT. | Health Technology |
NMD Pharma A/S
NMD Pharma A/S BiotechnologyHealth Technology NMD Pharma ApS engages with the research and preparation of small molecules targeting an undisclosed ion. It offers medical treatment of neuromuscular diseases for patients with chronic muscle wasting diseases such as myasthenia gravis and amyotrophic lateral sclerosis. The company was founded by Ole B?kgaard Nielsen, Thomas Holm Pedersen, and Claus Elsborg Olesen on May 7, 2015 and is headquartered in Aarhus, Denmark. | Health Technology |
Indalo Therapeutics, Inc.
Indalo Therapeutics, Inc. BiotechnologyHealth Technology Indalo Therapeutics, Inc. operates as a biopharmaceutical firm that develops integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The company was founded by David Griggs, Williamson Z. Bradford III, Peter Ruminski, and Robert W. Karr and is headquartered in Cambridge, MA. | Health Technology |
CTx Operations, Inc.
 CTx Operations, Inc. BiotechnologyHealth Technology CTx Operations, Inc. operates as a pre-clinical stage biotechnology company. It develops novel cellular therapeutics. The company was founded by Saar Gill and Michael Klichinsky in 2017 and is headquartered in Philadelphia, PA. | Health Technology |
Avenge Bio, Inc.
Avenge Bio, Inc. Pharmaceuticals: MajorHealth Technology Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation. | Health Technology |
K36 Therapeutics, Inc.
K36 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology K36 Therapeutics, Inc. develops small molecule therapeutics. The company is based in Cambridge, MA. The company was founded in 2021. The CEO is Terry Connolly. | Health Technology |
| Biohaven Ltd. |
- Stock Market
- Insiders
- Michael Heffernan
